Neurocrine Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.07.19	ALKS Settles Patent Suit, Once-Monthly Contraceptive In The Works, NBIX On Watch (RTTNews)
29.07.19	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Report (RTTNews)
29.04.19	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q1 Earnings Report (RTTNews)
12.03.19	Neurocrine Announces Interim Results From Phase II Study Of NBI-74788 (RTTNews)
05.02.19	Neurocrine Biosciences Inc Q4 Earnings Rise (RTTNews)
29.01.19	What's Making News At VYGR, NVCN, OCX, OrganiGram? (RTTNews)
29.01.19	Neurocrine Biosciences Gains Rights To Voyager's Four Gene Therapy Programs (RTTNews)
07.01.19	Neurocrine Biosciences Sees Higher Net Product Sale In Q4 (RTTNews)
13.12.18	AGTC Slumps After-hrs, NBIX Fails To Strike GOLD, IDRA To Report Data On Dec.14 (RTTNews)
12.12.18	Neurocrine Biosciences Announces Data From Phase IIb T-Force GOLD Study (RTTNews)
05.11.18	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q3 Earnings Report (RTTNews)
24.10.18	CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr. (RTTNews)
22.08.18	AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix (RTTNews)
02.08.18	MOH Boosts Outlook, NBIX Hits All-time High, ACER To Submit Its First NDA In Q4 (RTTNews)
31.07.18	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Report (RTTNews)
24.07.18	AbbVie Reports FDA Approval Of ORILISSA - Quick Facts (RTTNews)
29.06.18	Biotech Stocks Facing FDA Decision In July (RTTNews)
08.06.18	Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego (PR Newswire)
09.05.18	Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference (PR Newswire)
08.05.18	Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics (PR Newswire)
03.05.18	American Homes 4 Rent Reports First Quarter 2018 Financial and Operating Results (PR Newswire)
03.05.18	AKAO Slumps On FDA Panel Vote, ESPR Awaits Data In May, STAA Shines (RTTNews)
02.05.18	Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting (PR Newswire)
30.04.18	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q1 Earnings Report (RTTNews)
30.04.18	Neurocrine Biosciences Reports First Quarter 2018 Financial Results (PR Newswire)
27.04.18	AbbVie Presents New Investigational Data For Elagolix (RTTNews)
26.04.18	Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions (PR Newswire)
23.04.18	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results (PR Newswire)
21.04.18	An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) (RTTNews)
18.04.18	Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting (PR Newswire)
11.04.18	AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch (RTTNews)
10.04.18	AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain (RTTNews)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
07.03.18	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences (PR Newswire)
21.02.18	AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study (RTTNews)
14.02.18	Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data (PR Newswire)
13.02.18	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q4 Earnings Report (RTTNews)
13.02.18	Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 (PR Newswire)
08.02.18	Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference (PR Newswire)
06.02.18	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results (PR Newswire)
05.02.18	Hyundai's Super Bowl LII Commercial: "Hope Detector" (PR Newswire)
08.01.18	CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY (RTTNews)
07.01.18	Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer (PR Newswire)
07.01.18	Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones (PR Newswire)
05.01.18	LiveXLive Acquires Slacker Radio (PR Newswire)
07.12.17	Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (PR Newswire)
04.12.17	Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms (PR Newswire)
29.11.17	Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting (PR Newswire)
21.11.17	Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference (PR Newswire)
20.11.17	Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’299.00	2.40 %	K V
Holcim	89.04	1.09 %	K V
Roche Hldg G	266.90	0.95 %	K V
ABB	49.88	0.81 %	K V
Novartis	90.96	0.63 %	K V
Givaudan	3’882.00	-0.54 %	K V
Zurich Insur Gr	547.20	-0.83 %	K V
Alcon	76.34	-1.14 %	K V
Logitech Intl	78.74	-1.43 %	K V
Geberit	505.80	-1.52 %	K V

mehr

20.11.24		Anleger in New York halten sich zurück: NASDAQ Composite in der Verlustzone
30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell

20.11.24

Anleger in New York halten sich zurück: NASDAQ Composite in der Verlustzone

30.10.24

Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach

30.10.24

Handel in New York: NASDAQ Composite verbucht Verluste

30.10.24

Gute Stimmung in New York: NASDAQ Composite mittags fester

30.10.24

Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone

28.08.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter